CA3158513A1 - Methods for treating alzheimer's disease - Google Patents
Methods for treating alzheimer's diseaseInfo
- Publication number
- CA3158513A1 CA3158513A1 CA3158513A CA3158513A CA3158513A1 CA 3158513 A1 CA3158513 A1 CA 3158513A1 CA 3158513 A CA3158513 A CA 3158513A CA 3158513 A CA3158513 A CA 3158513A CA 3158513 A1 CA3158513 A1 CA 3158513A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- subject
- tau
- amount
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924633P | 2019-10-22 | 2019-10-22 | |
| US62/924,633 | 2019-10-22 | ||
| PCT/US2020/056676 WO2021081101A1 (en) | 2019-10-22 | 2020-10-21 | Anti-beta-amyloid antibody for treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3158513A1 true CA3158513A1 (en) | 2021-04-29 |
Family
ID=73344157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3158513A Pending CA3158513A1 (en) | 2019-10-22 | 2020-10-21 | Methods for treating alzheimer's disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220372123A1 (https=) |
| EP (1) | EP4048695A1 (https=) |
| JP (2) | JP2022553329A (https=) |
| KR (1) | KR20220084095A (https=) |
| CN (1) | CN114599393A (https=) |
| AU (1) | AU2020371612A1 (https=) |
| BR (1) | BR112022007595A2 (https=) |
| CA (1) | CA3158513A1 (https=) |
| CO (1) | CO2022004902A2 (https=) |
| IL (1) | IL292363A (https=) |
| JO (1) | JOP20220092A1 (https=) |
| MX (1) | MX2022004678A (https=) |
| WO (1) | WO2021081101A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2019152706A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a6a antibodies and methods of use thereof |
| US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2023081194A2 (en) * | 2021-11-03 | 2023-05-11 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
| AU2022439338A1 (en) * | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| WO2024086796A1 (en) * | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| US20240207362A1 (en) * | 2022-10-25 | 2024-06-27 | Institute For Basic Science (Ibs) | Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage |
| EP4455161A1 (en) | 2023-04-24 | 2024-10-30 | ONO Pharmaceutical Co., Ltd. | Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies |
| TW202530246A (zh) | 2023-09-15 | 2025-08-01 | 愛爾蘭商歐賽爾普羅希那有限公司 | 細胞穿透劑及其用途 |
| WO2025117721A1 (en) * | 2023-11-27 | 2025-06-05 | Massachusetts Institute Of Technology | Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081008A1 (en) | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| WO2008141321A1 (en) * | 2007-05-14 | 2008-11-20 | Medtronic, Inc. | Methods and device to neutralize soluble toxic agents in the brain |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2598882B1 (en) * | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| ME03008B (me) * | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| US20150315267A1 (en) * | 2012-12-07 | 2015-11-05 | Thierry Bussiere | A method of reducing brain amyloid plaques using anti-ab antibodies |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN114796481A (zh) * | 2016-06-07 | 2022-07-29 | 生物基因国际神经科学有限责任公司 | 治疗阿尔茨海默病的方法 |
-
2020
- 2020-10-21 KR KR1020227015913A patent/KR20220084095A/ko active Pending
- 2020-10-21 AU AU2020371612A patent/AU2020371612A1/en active Pending
- 2020-10-21 US US17/770,997 patent/US20220372123A1/en active Pending
- 2020-10-21 CA CA3158513A patent/CA3158513A1/en active Pending
- 2020-10-21 CN CN202080073830.0A patent/CN114599393A/zh active Pending
- 2020-10-21 IL IL292363A patent/IL292363A/en unknown
- 2020-10-21 EP EP20804740.7A patent/EP4048695A1/en active Pending
- 2020-10-21 JP JP2022523595A patent/JP2022553329A/ja active Pending
- 2020-10-21 BR BR112022007595A patent/BR112022007595A2/pt unknown
- 2020-10-21 MX MX2022004678A patent/MX2022004678A/es unknown
- 2020-10-21 WO PCT/US2020/056676 patent/WO2021081101A1/en not_active Ceased
-
2022
- 2022-04-19 CO CONC2022/0004902A patent/CO2022004902A2/es unknown
- 2022-04-20 JO JOP/2022/0092A patent/JOP20220092A1/ar unknown
-
2025
- 2025-10-27 JP JP2025181171A patent/JP2026012271A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021081101A1 (en) | 2021-04-29 |
| IL292363A (en) | 2022-06-01 |
| AU2020371612A1 (en) | 2022-05-19 |
| JP2026012271A (ja) | 2026-01-23 |
| CO2022004902A2 (es) | 2022-07-08 |
| BR112022007595A2 (pt) | 2022-08-23 |
| KR20220084095A (ko) | 2022-06-21 |
| JOP20220092A1 (ar) | 2023-01-30 |
| CN114599393A (zh) | 2022-06-07 |
| EP4048695A1 (en) | 2022-08-31 |
| US20220372123A1 (en) | 2022-11-24 |
| MX2022004678A (es) | 2022-08-15 |
| JP2022553329A (ja) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220372123A1 (en) | Anti-beta-amyloid antibody for treating alzheimer's disease | |
| US20260091109A1 (en) | Method for Treating Alzheimer's Disease | |
| US20220281963A1 (en) | Methods for treating alzheimer's disease | |
| JP2024525559A (ja) | アルツハイマー病治療用バイオマーカー | |
| JP2025506389A (ja) | ｐ－タウ１８１レベルを使用した治療方法 | |
| KR20250114372A (ko) | 타우(tau) pet 수준을 이용하는 치료 방법 | |
| US20250051427A1 (en) | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody | |
| US20240425573A1 (en) | Methods for treating alzheimer's disease | |
| US20240270830A1 (en) | Methods for treating alzheimer's disease | |
| TW202513583A (zh) | 使用抗Ａβ初原纖維抗體之治療方法 | |
| EA052963B1 (ru) | Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку | |
| NZ788486A (en) | Methods for treating Alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240924 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240924 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241021 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241021 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241126 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250630 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250704 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250710 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251009 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251009 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260415 |